Company Overview and News
2018-09-24 seekingalpha - 3
In this article, we want to shed light on a new Preferred Stock issued by AllianzGI Convertible & Income Fund II (NYSE:NCZ). Our goal is purely to inform you about the product while refraining ourselves from an investment recommendation. Even though the product might not be of interest to us and our financial objectives, it is definitely worth taking a look at.
begin 644 NCZPRA8A091118.pdf M)5!$1BTQ+C,*)79E
AllianzGI Convertible & Income Fund II As filed with the Securities and Exchange Commission on September 5, 2018 1933 Act File No. 333-225290 1940 Act File No. 811-21338 <
2018-09-06 sec.gov - 1
AllianzGI Convertible & Income Fund II SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
AllianzGI Convertible & Income Fund II Table of Contents Filed Pursuant to Rule 497(c) Registration Statement No. 333-225290 PROSPECTUS SUPPLEMENT (to Prospectus dated August 17, 2018)
AllianzGI Convertible & Income Fund II Filed pursuant to Rule 497(a) Rule 482 Ad Securities Act File No. 333-225290 Investment Company Act File No. 811-21338
AllianzGI Convertible & Income Fund II Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.
================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ----------------- FORM N-PX ----------------- ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-21338 ----------------- AllianzGI Convertible & Income Fund II (Exact name of registrant as specified in charter
AllianzGI Convertible & Income Fund II Table of Contents As filed with the Securities and Exchange Commission on August 15, 2018 1933 Act File No. 333-225290 1940 Act File No. 811-21338
AllianzGI Convertible & Income Fund II As filed with the Securities and Exchange Commission on August 1, 2018 SECURITIES
AllianzGI Convertible & Income Fund II As filed with the Securities and Exchange Commission on July 27, 2018 SECURITIES AND EXCHANGE COMMISSION
AllianzGI Convertible & Income Fund II Table of Contents As filed with the Securities and Exchange Commission on July 20, 2018 1933 Act File No. 333-225290 1940 Act File No. 811-21338
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET